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Abstract 1 
Background: The majority of research performed to date has examined the effects of 2 
commonly known antioxidants such as vitamins C, E and A, and carotenoids on age-related 3 
macular degeneration (AMD) risk and progression. To date, there is limited research on 4 
promising phytochemicals with antioxidant and anti-inflammatory properties, including 5 
flavonoids. 6 
Objectives: In this exploratory study, we aimed to assess the independent associations 7 
between dietary intake of total flavonoids and common flavonoid classes with the prevalence 8 
and 15-year incidence of AMD. 9 
Design: In this population-based cohort study, 2856 adults aged 49+ years at baseline and 10 
2037 followed up 15-years later were included in prevalence and incidence analysis, 11 
respectively. Dietary intake was assessed using a semi-quantitative food-frequency 12 
questionnaire (FFQ). Estimates of the flavonoid content of foods in the FFQ were assessed 13 
using the US Department of Agriculture Flavonoid, Isoflavone and Proanthocyanidin 14 
databases. AMD was assessed from retinal photographs.  15 
Results: In cross-sectional analysis, each 1-SD increase in total overall flavonoid intake was 16 
associated with reduced likelihood of any AMD, multivariable-adjusted OR 0.76 (95% CI 17 
0.58, 0.99). Each 1-SD increase in dietary intake of total flavonol and total flavanone was 18 
associated with reduced odds of prevalent any AMD: multivariable-adjusted OR 0.75 (95% 19 
CI 0.58, 0.97); and OR 0.77 (95% CI 0.60, 0.99), respectively. A marginally significant trend 20 
(p=0.05) was observed between increasing intake of total flavanone and hesperidin (from first 21 
to fourth quartile) and reduced likelihood of incident late AMD, after multivariable 22 
adjustment. Participants who reported one or more serves of oranges per day versus those 23 
who never ate oranges at baseline had reduced risk of late AMD 15 years later: multivariable-24 
adjusted OR 0.39 (95% CI 0.18, 0.85). 25 
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Conclusions: Our novel findings suggest an independent and protective association between 26 
dietary intake of flavonoids and the likelihood of having AMD. Additional prospective cohort 27 
studies are needed to validate these findings. 28 
 29 
Keywords: age-related macular degeneration; flavonoids; Blue Mountains Eye Study; 30 
Prevalence; Incidence.31 
5 
 
Introduction 32 
Age-related macular degeneration (AMD) is the leading cause of blindness and severe visual 33 
impairment in older adults (1). Current evidence suggests that AMD patients should be given 34 
dietary advice to increase consumption of dark green leafy vegetables, to consume low-35 
glycemic index diets, and to consume fish at least twice a week (2-6). The Age-Related Eye 36 
Disease Study (AREDS) demonstrated that taking a supplement containing high doses of 37 
vitamin C, vitamin E, beta-carotene, zinc, and copper could reduce AMD progression by 25% 38 
(7-12). A follow-up study (AREDS 2), found adding lutein and zeaxanthin (naturally 39 
occurring carotenoids) or omega-3 fatty acids to the original AREDS formulation (with beta-40 
carotene) had no overall effect on the risk of late AMD. However, the trial found that 41 
replacing beta-carotene with a 5-to-1 mixture of lutein and zeaxanthin could help to further 42 
reduce the risk of late AMD, particularly among people who had a low background dietary 43 
intake of lutein and zeaxanthin (5,6).  44 
The majority of research performed to date has examined the effects of commonly 45 
known antioxidants such as vitamins C, E and A, and carotenoids (lutein and zeaxanthin) on 46 
AMD risk and progression. There is limited research on promising phytochemicals with 47 
antioxidant and anti-inflammatory properties, including flavonoids (13). Flavonoids are 48 
bioactive compounds found in foods such as tea, chocolate, red wine, fruit, and vegetables 49 
(14). Flavonoids found in foods can be divided into six main flavonoid classes: flavonols, 50 
flavan-3-ols, flavones, flavanones, anthocyanins, and isoflavones (14,15). Flavonoids may 51 
have antioxidant and anti-inflammatory activities (15,16). There is also strong evidence that 52 
flavonoids positively impact vascular health through improved endothelial function (17). 53 
Thus, the role of flavonoids seem promising for reversing oxidative stress and inflammation-54 
associated damage and improving vascular function and thus, possibly improving the clinical 55 
features of AMD (13).  56 
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However, additional research is needed to establish whether flavonoid intake is 57 
beneficially associated with risk of AMD. Hence, we aimed to use a well characterized large 58 
cohort of adults aged 49+ years to explore: 1) Associations between dietary intake of total 59 
flavonoids with the prevalence and 15-year incidence of AMD (primary endpoints), 60 
independent of potential confounders; 2) Prospective relationship between six common 61 
flavonoid classes (flavonols, flavan-3-ols, flavones, flavanones, anthocyanins, and 62 
isoflavones) and key individual flavonoids (quercetin and hesperidin) with the prevalence and 63 
15-year incidence of AMD; and 3) Associations between the main foods and beverages 64 
contributing to total flavonoids e.g. tea, apples, oranges and orange juice, and both the 65 
prevalence and 15-year incidence of AMD. 66 
 67 
Methods 68 
Study population 69 
The Blue Mountains Eye Study (BMES) is a population-based cohort study of common eye 70 
diseases and other health outcomes in a suburban Australian population located west of 71 
Sydney. Study methods and procedures have been described elsewhere (18). Baseline 72 
examinations of 3654 residents aged >49 years were conducted during 1992-4 (BMES-1; 73 
82.4% participation rate). Selection bias at baseline was minimised after multiple call-back 74 
visits, including door-knocking, telephone reminders and letters at recruitment. Surviving 75 
baseline participants were invited to attend examinations after 5- (1997-9, BMES-2), 10- 76 
(2002-4, BMES-3), and 15 years (2007-9, BMES-4) at which 2334 (75.1% of survivors), 77 
1952 participants (75.6% of survivors) and 1149 (55.4% of survivors) were re-examined, 78 
respectively. Participants who did not return to the 5-year visit were also invited to the 10- or 79 
15-year visits. For the current report we analyzed data from BMES-1 through to BMES-4. 80 
The University of Sydney and the Western Sydney Area Human Ethics Committees approved 81 
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the study including all methods that were performed, and written informed consent was 82 
obtained from all participants at each examination. All methods in this study were performed 83 
in accordance with the relevant guidelines and regulations. 84 
 85 
Assessment of AMD 86 
We took two 30° stereoscopic color retinal photographs of the macula of both eyes, which 87 
were graded for presence of early and late AMD using the Wisconsin AMD Grading System 88 
(19,20). Inter- and intra-grader reliability showed good agreement for grading of specific 89 
AMD lesions with quadratic weighted kappa values ranging from 0.64 to 0.93 and 0.54-0.94 90 
respectively (21). The detailed methodology of AMD ascertainment in this population has 91 
been previously reported (19,20). Early AMD was defined as the absence of late AMD and 92 
presence of either: 1) large (>125-µm diameter) indistinct soft or reticular drusen or 2) both 93 
large distinct soft drusen and retinal pigmentary abnormalities (hyperpigmentation or 94 
hypopigmentation) in either eye (20). Similarly, late AMD was defined as the presence of 95 
neovascular AMD or geographic atrophy in either eye (20). Any AMD was defined as having 96 
early or late AMD. A retinal specialist (P.M.) adjudicated all uncertain retinal pathology and 97 
confirmed all late AMD cases.  98 
 99 
Assessment of flavonoid intake 100 
Dietary data were collected using a 145-item self-administered food frequency questionnaire 101 
(FFQ). The FFQ is modified for Australian diet and vernacular from an early Willett FFQ 102 
(22) and includes reference portion sizes. Participants used a 9-category frequency scale to 103 
indicate the usual frequency of consuming individual food items during the past year. Foods 104 
listed in the FFQ were categorized into major food categories and subcategories similar to 105 
those used for the 1995 Australian National Nutrition Survey (23). Estimates of the flavonoid 106 
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content of foods in the FFQ were derived from the US Department of Agriculture (USDA) 107 
Database for the Flavonoid Content of Selected Foods (24), USDA Database for the 108 
Isoflavone Content of Selected Foods (25) and USDA Database for the Proanthocyanidin 109 
Content of Selected Foods (26).  110 
The method of computing the flavonoid content of foods was similar to that outlined in 111 
Mink et al. (27) Specifically, for each food, we computed the intake of each individual 112 
flavonoid compound present in the food, the sum of assessed flavonoids for each flavonoid 113 
class, by summing the individual compounds of each flavonoid class, and the sum of all 114 
flavonoid intakes, by summing the flavonoid classes. The flavan-3-ol content of foods was 115 
considered to represent the average of total flavan-3-ol and proanthocyanidin monomer 116 
contents. For foods where only the flavan-3-ol or proanthocyanidin monomer content was 117 
available, the single value provided was used to represent the flavan-3-ol content. The 118 
proanthocyanidin content of foods was calculated by summing the proanthocyanidin dimers, 119 
trimers, 4–6mers, 7–10mers and polymers. Where multiple varieties of a food listed in the 120 
FFQ were reported in the databases, the average flavonoid content of all similar varieties was 121 
computed, consistent with the descriptors used in the FFQ output. Foods in the FFQ that were 122 
not in the flavonoid databases were assumed to contain no flavonoids. Intakes of flavonoid 123 
classes (in mg/d) were calculated by multiplying the estimated intake (g edible portion/d) 124 
from the FFQ, with the flavonoid class content (mg/d edible portion) of each food item on the 125 
questionnaire. Some of the food items on the FFQ with multiple ingredients (e.g., pizza) were 126 
assigned a weighted value on the basis of a USDA standard recipe.  127 
 128 
Assessment of covariates 129 
Participants self-reported smoking status as: never smoked; past smoker; or current smoker. 130 
We extracted separate data on the frequency of consuming fish (e.g. salmon, tuna and 131 
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sardines) and dietary intakes of lutein and zeaxanthin from the FFQ. The United States 132 
Department of Agriculture Carotenoid Food Composition database (28) was used to estimate 133 
the intakes of other combined lutein and zeaxanthin. Genotypic status was available for the 134 
complement factor H (CFH) single nucleotide polymorphism (SNP) rs1061170 in 2041 135 
baseline participants who returned at BMES2 and for the age-related maculopathy 136 
susceptibility gene 2 (ARMS2) SNP rs10490924 in 1893 baseline participants who returned at 137 
BMES2. Two sources of genotypic information were used (29). TaqMan assays (Applied 138 
Biosystems, Foster City, CA), had been performed to provide specific genotyping of 139 
rs1061170 in 1925 individuals and rs10490924 in 638 individuals. In addition, BMES 140 
genotyping was also carried out for a genome-wide association study (GWAS) using a 141 
custom array (Human 670-Quad, version 1, Illumina Inc) at the Wellcome Trust Centre for 142 
Human Genetics, Sanger Institute, Cambridge, UK, as part of the Wellcome Trust Case 143 
Control Consortium 2. After quality control, genotype imputation was performed using a 144 
genetic variation catalogue (1000 Genomes, version 1) and IMPUTE software. Imputed 145 
genotypic status was available for rs1061170 in 1657 baseline participants who returned at 146 
BMES2 and rs10490924 in 1802 baseline participants who returned at BMES2. This 147 
information on genotyping status from imputed data was used where TaqMan assays were 148 
not available, for rs1061170 in 116 individuals and for rs10490924 in 1255 individuals. 149 
Concordance rates between typed and imputed SNP values were 99.6% for rs1061170 and 150 
99.2% for rs10490924. Imputation data metrics were as follows: imputation R2 values were 151 
0.968 for rs1061170 and 0.996 for rs10490924, the proportion of the sample with missing 152 
SNP information was 8.8% for rs1061170 and 0.5% for rs10490924, Hardy Weinberg 153 
equilibrium p values were 0.79 for rs1061170 and 0.95 for rs10490924, minor allele 154 
frequencies were 0.39 for rs1061170 and 0.22 for rs10490924.  155 
 156 
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Statistical analysis 157 
In exploratory analyses, we assessed associations with the prevalence and 15-year incidence 158 
of AMD, which were the primary endpoints. These primary endpoints did not change during 159 
the course of the present study or during post-hoc analyses. SAS statistical software (SAS 160 
Institute, Cary NC) version 9.4 was used for analyses. Energy-adjusted dietary flavonoid 161 
intakes were transformed to normal scores using the Blom method. Associations between 162 
energy-adjusted baseline dietary flavonoid intakes (study factor) and prevalence of AMD 163 
(study outcome) were examined using logistic regression analysis. Further, associations 164 
between energy-adjusted baseline dietary flavonoid intakes and 15-year cumulative incidence 165 
of AMD were examined in discrete logistic regression models. The discrete logistic model 166 
refers to a survival model in which event times are treated as being genuinely discrete in 167 
truth, rather than being on a continuous spectrum. The discrete time hazard is related to 168 
covariates by a logistic regression equation (30,31). We have used its implementation in SAS 169 
in proc phreg, where a partial likelihood estimation method is used. Findings were also 170 
examined after accounting for the competing risk of death using Fine and Gray’s model (32) 171 
for cumulative incidence in the presence of competing risks. Regression analysis was first 172 
adjusted for age and sex, and then for covariates that have been found to be associated with 173 
incidence of AMD in the BMES cohort: current smoking, fish consumption, intakes of lutein 174 
and zeaxanthin, and the presence of CFH and ARMS2 SNPs, rs1061170 and rs10490924, 175 
respectively. Genotype status was included as an adjustment factor in multivariable-adjusted 176 
models using three categories (no minor alleles, one minor allele only, or two minor alleles), 177 
based on an additive model for genetic effects. Further adjustments for BMI, hypertension, 178 
physical activity (in metabolic equivalents) and dietary vitamin C intake were also considered 179 
but did not appreciably change the observed estimates, so were not included in the main 180 
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analysis. Findings from all analyses are expressed as adjusted odds ratios (OR) with 95% 181 
confidence intervals (CI).  182 
 183 
Results 184 
Prevalence of AMD 185 
Of the 3654 subjects examined at baseline, 2856 who had complete dietary data as well as 186 
information on AMD lesions were included in the prevalence analysis (Supplemental Figure 187 
1). Study characteristics of participants included in cross-sectional analysis are shown in 188 
Table 1. At baseline, there were 4.6% and 1.7% participants with early and late AMD, 189 
respectively (Table 1). After multivariable-adjustment, each 1-SD increase in intake of total 190 
flavonoids was associated with reduced likelihood of any AMD, OR 0.76 (95% CI 0.58, 191 
0.99). Each 1-SD increase in intake of total flavonol and total flavanone was associated with 192 
reduced odds of any AMD: OR 0.75 (95% CI 0.58, 0.97); and OR 0.77 (95% CI 0.60, 0.99), 193 
respectively. Supplementary analysis involved key individual flavonoids - quercetin (a 194 
flavonol) and hesperidin (flavanone), and prevalence of AMD. After adjusting for all 195 
potential confounders, each 1-SD increase in intake of quercetin was associated with reduced 196 
odds of any AMD: OR 0.76 (95% CI 0.58, 0.99). No significant linear associations were 197 
observed between hesperidin and prevalence of AMD (data not shown).  198 
Table 2 shows the association between quartiles of intake of flavonoids and prevalence 199 
of AMD. Participants in the highest quartile of total flavanone intake compared to those in 200 
the lowest quartile of intake had reduced odds of any and early AMD. Those in the highest 201 
versus lowest quartile of total flavonol intake had a 57% reduced likelihood of any AMD, 202 
after multivariable adjustment. Participants in the highest quartile of total hesperidin intake 203 
compared to those in the lowest quartile of intake had reduced odds of any and early AMD 204 
(Table 2).  205 
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Additional analysis involved investigating the main foods and beverages contributing to 206 
total flavonoids, flavonols, and flavanones i.e. apples, oranges, tea and orange juice. 207 
Compared to participants who did not consume any oranges (reference group), those who 208 
reported having one or more serves of oranges per week but less than one serve per day had 209 
reduced odds of any AMD: multivariable-adjusted OR 0.42 (95% CI 0.21, 0.84). Similarly, 210 
participants who reported one or more serves of oranges per day compared to the reference 211 
group had reduced odds of any AMD OR 0.42 (95% CI 0.20, 0.89). Also, compared to 212 
participants who did not consume any oranges, participants who ate one or more serves of 213 
oranges per week but had less than one serve per day had 92% reduced odds of late AMD: 214 
OR 0.08 (95% CI 0.01, 0.76). Participants who consumed one or more serves of orange juice 215 
per day compared to those who never consumed orange juice had reduced likelihood of 216 
having early AMD: multivariable-adjusted OR 0.35 (95% CI 0.14, 0.85). No significant 217 
associations were observed between consumption of apples, tea, red wine and beer with 218 
prevalence of AMD (data not shown).  219 
 220 
Incidence of AMD 221 
Of the 2856 included in the prevalence analysis, 2037 participants with complete AMD and 222 
lifestyle data were re-examined 5, 10 and/or 15 years later (i.e. at least one follow-up 223 
examination), and therefore included in incidence analysis (Supplemental Figure 1). Baseline 224 
characteristics of participants included in longitudinal analysis are shown in Table 1. There 225 
were 15.3% and 4.1% incident early and late AMD cases, respectively. No significant linear 226 
associations were observed between flavonoid intake and 15-year incidence of AMD (data 227 
not shown). A marginally significant trend was observed between increasing intake of total 228 
hesperidin (from first to fourth quartile) and lower 15-year incidence of late AMD, after 229 
multivariable adjustment (Table 3). Findings were essentially similar after accounting for the 230 
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competing risk of death, except that the trend across quartiles of hesperidin became 231 
marginally non-significant (p=0.06), while a significant trend emerged between quartiles of 232 
increasing flavonol intake and increased incidence of early AMD (p=0.03). Participants who 233 
reported one or more serves of oranges per day versus those who never ate oranges at 234 
baseline had reduced risk of incident late AMD 15 years later: multivariable-adjusted OR 235 
0.39 (95% CI 0.18, 0.85). No significant associations were observed between consumption of 236 
apples, orange juice, tea, red wine and beer with the 15-year incidence of AMD (data not 237 
shown).  238 
 239 
Discussion  240 
This prospective cohort study of older adults provides novel epidemiological evidence of an 241 
independent association between total flavonoid intake as well as the intake of specific 242 
flavonoid classes and AMD. Specifically, we observed significant and protective associations 243 
between the intake of total flavonoids as well as total flavonol and total flavanone intake with 244 
AMD prevalence. Modest associations were also observed between the intakes of total 245 
flavone, flavanone and hesperidin and risk of incident late AMD 15 years later. Our study 246 
suggests that consumption of oranges (a key contributor to total flavanone) is inversely and 247 
independently associated with both prevalence and incidence of late AMD.  248 
The median intake of total flavonoids in our cohort was 875 mg/day which is higher 249 
than that previously reported in a Western Australia cohort (median intake of 696-mg/d in 250 
women aged >75 years) (14) and in an Australia-wide nutrition survey (median intake of 454 251 
mg/day in those aged 19+years) (33). This difference is likely to be due to variations in age-252 
distribution, However, variations in food content databases and the different dietary 253 
assessment methods administered could also explain the differences in flavonoid intake 254 
observed between studies (14). 255 
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Higher total overall flavonoid intake and intake of particular flavonoid subgroups e.g. 256 
flavonol and flavanone, were associated with reduced odds of having AMD. This observed 257 
association is in line with existing evidence, as flavonoids are found in abundance in fruits 258 
and vegetables (15) and adequate consumption of fruits and vegetables has been established 259 
as being protective against AMD (2,34). Our findings also concur with the existing published 260 
literature which has shown that following consumption, flavonoids may contribute to a 261 
variety of beneficial biological activities in humans (14). There is robust data now showing 262 
that flavonoids can preserve and enhance nitric oxide status and improve endothelial function 263 
(35,36). There is also evidence that these compounds can minimize oxidative damage and 264 
inflammation (15,16). Moreover, among the known angiogenesis inhibitors, flavonoids seem 265 
to play an important role (37). While, the mechanism behind the antiangiogenic effect of 266 
flavonoids is unclear, one proposed pathway is through inhibition of protein kinases (2). 267 
Overall, these salutary effects of flavonoids may help to explain the influence these dietary 268 
compounds might have on AMD pathogenic processes, that is, the inflammatory, oxidative 269 
and angiogenic pathways (38).  270 
The associations between flavonoid intake and both AMD prevalence and incidence 271 
appear to be class dependent. Specifically, participants with higher intakes of flavonol and 272 
flavanone had reduced odds of any AMD, while other flavonoid classes such as flavan-3-ols 273 
and isoflavone did not show any significant associations with AMD prevalence. Similarly, 274 
differential associations with 15-year incidence of AMD were observed e.g. flavone and 275 
flavanone intakes were inversely associated with risk of incident AMD while other flavonoid 276 
subgroups were not. The varying structures and bioactivities of the different flavonoid 277 
classes, as well as the ability to adequately assess intakes from foods could explain the 278 
differential associations observed between the individual flavonoid classes and AMD 279 
prevalence and incidence (14,39). Indeed, even a minor structural difference in flavonoids 280 
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can have a large impact on their bioavailability (40,41). Further studies are needed to confirm 281 
our findings and elucidate the influence of total flavonoids and flavonoid subclasses on the 282 
development and progression of AMD in older adults.   283 
Our findings are promising, as BMES data show for the first time that flavonoids may 284 
be useful food compounds in protecting against AMD. Oral bioavailability of flavonoids, 285 
however, is known to be limited by poor intrinsic transmembrane diffusion characteristics 286 
and poor solubility (42). Moreover, the activity of the flavonoid metabolites is not well 287 
established (42). Further research is also needed to establish whether systemic administration 288 
of flavonoids will yield much higher and effective concentrations of the parent flavonoids in 289 
the ocular tissues and at much lower doses (42). For the time being, it is reasonable that 290 
adequate intake of fruits (particularly oranges), vegetables, and beverages (e.g. orange juice) 291 
containing flavonoids be recommended to patients, although it is too early to make 292 
recommendations on daily flavonoid intakes for prevention of AMD (15). Strengths of this 293 
study include its prospective data collection, long-term follow-up of a population-based 294 
sample, use of a validated FFQ and careful adjustment for confounders including genetic risk. 295 
Hence, our findings are applicable to the general older Australian population and could also 296 
be applicable to older adults in other Western countries. Additionally, this study uses high 297 
quality stereoscopic retinal photography with validated grading to assess macular conditions, 298 
and a detailed side-by-side comparison of the baseline and follow-up photographs to ensure 299 
negligible misclassification of incident AMD (4,43,44). However, this study has some 300 
noteworthy limitations. First, the database used for the estimation of flavonoid content of 301 
foods is based on US data only and therefore this approach might not have accounted for any 302 
variation in the flavonoid content of foods found in Australia (40). Second, we cannot 303 
discount the effect of residual confounding from unmeasured or unaccounted factors (e.g. 304 
inflammatory markers) on observed associations. Finally, the number of participants who 305 
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developed incident AMD was small, and this might have reduced power to detect modest 306 
associations with flavonoid intake. 307 
In summary, we report novel independent associations between dietary intake of total 308 
flavonoids, and some of the common flavonoid classes (e.g. flavonol and flavanone) and 309 
AMD among older adults. Further, oranges and orange juice, one of the main foods and 310 
beverages contributing to total flavanone, is also likely to independently influence risk of 311 
AMD. These findings suggest that a habitual diet high in flavonoids could play a role in 312 
AMD prevention and progression. These associations, if confirmed in other epidemiological 313 
and intervention studies could have important public health implications.    314 
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Table 1. Baseline characteristics of participants involved in prevalence and 15-year incidence 
age-related macular degeneration (AMD) analysis 
Characteristics 
Prevalence 
(n=2856) 
Incidence 
(n=2037) 
Age, yrs 65.3 (9.3) 63.8 (8.3) 
Males 1259 (44.1) 881 (43.3) 
Current smokers 393 (14.2) 247 (12.4) 
Fish consumption (≥1 serve/ week) 1690 (59.8) 1200 (59.4) 
Presence of one or two AMD risk 
alleles 
 
 
CFH-rs1061170 1077 (60.9) 1051 (60.6) 
ARMS2-rs10490924 629 (38.4) 607 (37.9) 
AMD type   
Early 130 (4.6) 268 (15.3) 
Late 47 (1.7) 84 (4.1) 
Data is presented as mean (±SD) or n (%) and p-values were obtained using t-tests for 
continuous variables and chi-square analyses for categorical data.
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Table 2. Associations between flavonoid intake and prevalence of age-related macular 
degeneration (AMD) in the Blue Mountains Eye Study (n=2856) 
 
  
Any AMD 
(n=177) 
Early AMD 
(n=130) 
Late AMD 
(n=47) 
Flavonoids (mg/day)  
Adjusted OR 
(95% CI)  
Adjusted OR 
(95% CI)  
Adjusted OR 
(95% CI)  
All flavonoids1     
1st quartile (≤410.6)  1.0 (reference) 1.0 (reference) 1.0 (reference) 
2nd quartile (412.4-881.5)  0.63 (0.31, 1.29) 0.51 (0.23, 1.14) 1.37 (0.31, 6.13) 
3rd quartile (881.6-1232.3)  0.62 (0.31, 1.24) 0.63 (0.30, 1.32) 0.60 (0.11, 3.10) 
4th quartile (≥1232.4)  0.52 (0.25, 1.06) 0.52 (0.24, 1.12) 0.45 (0.08, 2.60) 
P for trend  0.08 0.12 0.25 
Total flavonol1     
1st quartile (≤18.2)  1.0 (reference) 1.0 (reference) 1.0 (reference) 
2nd quartile (18.3-34.6)  0.43 (0.20, 0.90) 0.46 (0.20, 1.07) 0.28 (0.06, 1.28) 
3rd quartile (34.6-46.0)  0.70 (0.36, 1.36) 0.82 (0.40, 1.69) 0.33 (0.08, 1.38) 
4th quartile (≥46.0)  0.43 (0.21, 0.88) 0.48 (0.22, 1.07) 0.22 (0.04, 1.02) 
P for trend  0.05 0.16 0.05 
Total flavanone1     
1st quartile (≤9.6)  1.0 (reference) 1.0 (reference) 1.0 (reference) 
2nd quartile (9.6-25.1)  0.51 (0.24, 1.06) 0.34 (0.14, 0.83) 1.61 (0.40, 6.50) 
3rd quartile (25.2-47.1)  1.01 (0.55, 1.85) 1.05 (0.55, 1.99) 0.84 (0.18, 3.94) 
4th quartile (≥47.2)  0.29 (0.13, 0.66) 0.25 (0.10, 0.63) 0.65 (0.10, 4.06) 
P for trend  0.01 0.02 0.46 
Total quercetin     
1st quartile (≤12.3)  1.0 (reference) 1.0 (reference) 1.0 (reference) 
2nd quartile (12.3-20.8)  0.46 (0.22, 0.99) 0.52 (0.23, 1.18) 0.26 (0.05, 1.48) 
3rd quartile (20.8-26.9)  0.73 (0.37, 1.43) 0.76 (0.36, 1.60) 0.65 (0.17, 2.52) 
4th quartile (≥26.9)  0.49 (0.24, 1.00) 0.53 (0.24, 1.17) 0.27 (0.05, 1.39) 
P for trend  0.12 0.21 0.20 
Total hesperidin     
1st quartile (≤5.5)  1.0 (reference) 1.0 (reference) 1.0 (reference) 
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2nd quartile (5.5-16.0)  0.63 (0.31, 1.26) 0.49 (0.22, 1.09) 1.44 (0.36, 5.85) 
3rd quartile (16.0-30.1)  0.76 (0.40, 1.46) 0.78 (0.39, 1.54) 0.76 (0.15, 3.96) 
4th quartile (≥30.2)  0.47 (0.23, 0.97) 0.43 (0.19, 0.93) 0.92 (0.18, 4.74) 
P for trend  0.08 0.10 0.70 
OR – odds ratio; CI – confidence intervals. Bolded values represent significant associations 
(p <0.05) in comparison to the reference group. 
1 Values were calculated by using logistic regression analyses and were adjusted for age, sex, 
current smoking, fish consumption, intakes of lutein and zeaxanthin, and CFH and ARMS2 
SNPS (rs1061170 and rs10490924). 
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Table 3. Associations between flavonoid intake and 15-year incidence of age-related macular 
degeneration (AMD) in the Blue Mountains Eye Study (n=2037) 
  
Early AMD 
(n=268) 
Late AMD 
(n=84) 
Flavonoids (mg/day)  
Adjusted OR 
(95% CI)  
Adjusted OR 
(95% CI)  
All flavonoids1    
1st quartile (≤410.1)  1.0 (reference) 1.0 (reference) 
2nd quartile (413.0-881.5)  1.13 (0.75, 1.71) 0.72 (0.33, 1.58) 
3rd quartile (882.0-1232.3)  0.94 (0.62, 1.42) 1.17 (0.60, 2.29) 
4th quartile (≥1232.4)  1.22 (0.82, 1.81) 1.00 (0.50, 2.00) 
P for trend  0.35 0.65 
Total flavone1    
1st quartile (≤0.64)  1.0 (reference) 1.0 (reference) 
2nd quartile (0.7-1.0)  0.97 (0.66, 1.44) 2.36 (1.13, 5.01) 
3rd quartile (1.0-1.5)  0.83 (0.56, 1.23) 1.46 (0.66, 3.23) 
4th quartile (≥1.5)  0.75 (0.50, 1.11) 1.52 (0.66, 3.49) 
P for trend  0.10 0.97 
Total flavanone1    
1st quartile (≤9.6)  1.0 (reference) 1.0 (reference) 
2nd quartile (9.6-25.1)  0.92 (0.62, 1.38) 1.15 (0.62, 2.11) 
3rd quartile (25.2-47.1)  0.97 (0.67, 1.41) 0.69 (0.36, 1.32) 
4th quartile (≥47.2)  0.82 (0.55, 1.22) 0.55 (0.27, 1.09) 
P for trend  0.30 0.05  
Total hesperidin1     
1st quartile (≤5.5)  1.0 (reference) 1.0 (reference)  
2nd quartile (5.5-16.0)  1.03 (0.69, 1.53) 1.22 (0.65, 2.27)  
3rd quartile (16.0-30.1)  1.11 (0.76, 1.62) 0.88 (0.46, 1.68)  
4th quartile (≥30.2)  0.85 (0.57, 1.26) 0.54 (0.26, 1.13)  
P for trend  0.32 0.05  
OR – odds ratio; CI – confidence intervals. Bolded values represent significant associations 
(p <0.05) in comparison to the reference group.  
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1 Values were calculated by using discrete logistic regression models and were adjusted for 
age, sex, current smoking, fish consumption, intakes of lutein and zeaxanthin, and CFH and 
ARMS2 SNPS (rs1061170 and rs10490924). 
 
 
 
 
 
 
 
 
 
